Your session is about to expire
← Back to Search
Pembrolizumab +/− Anetumab Ravtansine for Mesothelioma
Study Summary
This trial is testing pembrolizumab with or without anetumab ravtansine to treat mesothelin-positive pleural mesothelioma. Anetumab ravtansine is a monoclonal antibody that is linked to a chemotherapy drug. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not taking any strong medication that affects liver enzymes.I haven't had monoclonal antibody therapy in the last 4 weeks.My tumor shows high levels of mesothelin in more than 30% of its cells.You are currently taking any other experimental medications.I am allergic to medications similar to anetumab ravtansine or pembrolizumab.I have a history of hepatitis B or an active hepatitis C infection.You have a low white blood cell count.Your total bilirubin levels are within the normal range for the hospital where you are being treated.I can understand and am willing to sign the consent form, or I have someone who can do it for me.My blood clotting tests are within normal limits or I am on a stable blood thinner dose.Women who could become pregnant must have a negative pregnancy test.I am not taking any excluded medications during this trial.I am not pregnant or breastfeeding.I have been treated with a PD-1, PD-L1, or PD-L2 inhibitor before.I do not have worsening brain cancer symptoms or need steroids for them.I haven't received blood products or colony stimulating factors in the last 4 weeks.My cancer diagnosis of mesothelioma has been confirmed by lab tests.I have been treated with platinum-based therapy, with or without bevacizumab.I am mostly self-sufficient and can carry out daily activities.You have HIV and do not meet certain requirements.I have received platinum-based chemotherapy.My kidney function, measured by creatinine levels or clearance, is within the normal range.You have a platelet count of at least 100,000 per microliter.I am willing to provide a tissue sample for mesothelin testing.Your AST and ALT levels in the blood are not more than 2.5 times the upper limit of normal.I have another cancer that is getting worse or needs treatment.I do not have a history of corneal epitheliopathy.Your body has enough infection-fighting white blood cells.I have no lasting side effects from previous cancer treatments above mild.My cancer can be measured using specific criteria.I have or had lung inflammation treated with steroids.
- Group 1: Group I (pembrolizumab)
- Group 2: Group II (anetumab ravtansine, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many study participants are being monitored in this research?
"This clinical trial is not currently searching for patients at this time. The trial was initially posted on 2/8/2018 and was last edited on 10/18/2022. If you are searching for other studies, there are presently 158 studies actively looking for patients with mesothelioma, malignant and 1002 trials for Pharmacological Study actively recruiting participants."
How many locations are conducting this experiment?
"Currently, this study is operational in 27 locations. While some sites are in Phoenix, Creve Coeur and Saint Louis, there are also other centres located throughout the country. To limit travel burden, patients should aim to select the site that is geographically closest to them."
Are people still being signed up to participate in this clinical trial?
"This study is not recruiting at this time, as reflected by the trial's last update on October 18th, 2022. If you are seeking other trials to participate in, there are 1002 pharmacological studies and 158 clinical trials for patients with mesothelioma that are still admitting patients."
Could you name a few other research projects that have used this same drug in their tests?
"There are currently one thousand and two ongoing clinical trials for Pharmacological Study. Out of these, 122 have reached Phase 3. Many of theHouston-based trials are nearing their completion; however, there are still 36,098 sites around the world investigating this topic."
Why do doctors most often prescribe this medication?
"Pharmacological Study is an effective treatment for malignant neoplasms, unresectable melanoma, and microsatellite instability high."
Share this study with friends
Copy Link
Messenger